Table 3.

Multivariate Cox proportional hazards model for BRFS in association with % of cells in patients with CAPRA-S scores less than 5 and without adverse pathological features (positive surgical margin, seminal vesicle invasion, or lymph node involvement)

Variable	Model without PTEN loss (% cells)				Model with PTEN loss (% cells)
	Training cohort		Validation cohort		Training cohort		Validation cohort
	HR (95% CI)	P *	HR (95% CI)	P *	HR (95% CI)	P *	HR (95% CI)	P *
ERG fusion (Yes vs No)	0.78 (0.39 to 1.56)	.49	1.38 (0.62 to 3.10)	.43	0.77 (0.39 to 1.54)	.46	1.32 (0.58 to 2.97)	.51
CAPRA-S (1-unit increase)	1.49 (1.13 to 1.96)	.005	1.46 (1.06 to 2.02)	.02	1.49 (1.13 to 1.97)	.005	1.42 (1.02 to 1.99)	.04
PTEN loss (% cells)
>65% vs intact (0%–65%)†	—	—	—	—	2.36 (1.06 to 5.26)	.036	5.52 (2.36 to 12.90)	<.001
C-index (SE) of the model	0.66 (0.04)		0.62 (0.05)		0.68 (0.04)		0.69 (0.05)

^*Two-sided log-rank test. BRFS = biochemical recurrence-free survival; CAPR-S = Cancer of the Prostate Risk Assessment Postsurgical; CI = confidence interval; HR = hazard ratio; PSA = prostate specific antigen; PTEN = phosphatase and tensin homolog.

^†0%–65% group includes PTEN intact cases.